{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:47:27Z","timestamp":1777873647441,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82530110"],"award-info":[{"award-number":["82530110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["JC202305"],"award-info":[{"award-number":["JC202305"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpba.2026.117435","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:47:14Z","timestamp":1771832834000},"page":"117435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of an efficient and sensitive LC-MS\/MS assay for simultaneous determination of the high frequency used antibody drug conjugate payload MMAE and anti-vascular tyrosine kinase inhibitor lenvatinib in human plasma"],"prefix":"10.1016","volume":"274","author":[{"given":"Yongqing","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-4610","authenticated-orcid":false,"given":"Yuanyuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117435_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/mabs.27436","article-title":"Antibody-drug conjugates: present and future","volume":"6","author":"Beck","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117435_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib3","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jtho.2022.07.152","article-title":"MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC","volume":"17","author":"Levy","year":"2022","journal-title":"J. Thorac Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib4","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpba.2026.117435_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jpba.2026.117435_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/ph13120462","article-title":"Analytical methods for the detection and quantification of ADCs in biological matrices","volume":"13","author":"Cahuzac","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2026.117435_bib8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2026.117435_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61522-4","article-title":"A simple and highly sensitive LC-MS workflow for characterization and quantification of ADC cleavable payloads","volume":"14","author":"Mak","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2026.117435_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab soravtansine: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2026.117435_bib11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ymthe.2024.02.020","article-title":"Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release","volume":"32","author":"Zheng","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jpba.2026.117435_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117435_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2026.117435_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jpba.2026.117435_bib17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/cas.15719","article-title":"Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1+ CD8+ T cells in HCC via blocking VEGFR2","volume":"114","author":"Mei","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jpba.2026.117435_bib18","article-title":"A rapid, simple and sensitive LC-MS\/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring","volume":"16","author":"Nchetta","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2026.117435_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097647","article-title":"Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial","volume":"16","author":"Yang","year":"2026","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpba.2026.117435_bib21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab Vedotin: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2026.117435_bib22","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2026.117435_bib23","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, M10 Bioanalytical method validation, 2022, \u3008https:\/\/www.ich.org\/page\/multidisciplinary-guidelines\u3009."},{"key":"10.1016\/j.jpba.2026.117435_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117435_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jpba.2026.117435_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4155\/bio-2023-0189","article-title":"Bioanalysis of the Bicycle\u00ae toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry","volume":"16","author":"Tweed","year":"2024","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117435_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4855","article-title":"Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics","volume":"34","author":"Lee","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2026.117435_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116318","article-title":"Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin\u20114\u2011targeting antibody\u2011drug conjugate","volume":"248","author":"Fang","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117435_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","article-title":"Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"22","author":"Ikeda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2026.117435_bib31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bcp.12907","article-title":"Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer","volume":"81","author":"Gupta","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117435_bib32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00280-020-04178-x","article-title":"Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma","volume":"86","author":"Hata","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117435_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","article-title":"Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer","volume":"36","author":"Nagahama","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jpba.2026.117435_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-024-04746-5","article-title":"Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma","volume":"95","author":"Meertens","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117435_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2026.117435_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114161","article-title":"Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC\u2011MS\/MS","volume":"202","author":"Ye","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117435_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2012.01.004","article-title":"Development and validation of LC-MS\/MS assays for the quantification of E7080 and metabolites in various human biological matrices","volume":"887\u2013888","author":"Dubbelman","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2026.117435_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259137","article-title":"A rapid, simple and sensitive LC-MS\/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring","volume":"16","author":"Zanchetta","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2026.117435_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.22159\/ajpcr.2017.v10i7.18287","article-title":"Development and validation of liquid chromatography coupled with tandem mass spectrometry method for estimation of lenvatinib in human plasma","volume":"10","author":"Srikanth","year":"2017","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/j.jpba.2026.117435_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/FTD.0000000000000872","article-title":"A broad range high-throughput assay for lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry with clinical application in patients with hepatocellular carcinoma","volume":"43","author":"Sueshige","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2026.117435_bib41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:08:18Z","timestamp":1777572498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"alternative-id":["S0731708526001032"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117435","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an efficient and sensitive LC-MS\/MS assay for simultaneous determination of the high frequency used antibody drug conjugate payload MMAE and anti-vascular tyrosine kinase inhibitor lenvatinib in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117435"}}